IL-1α and Complement Cooperate in Triggering Local Neutrophilic Inflammation in Response to Adenovirus and Eliminating Virus-Containing Cells

PLoS Pathogens

Volumn 10, Issue 3, 2014, Pages

  Di Paolo, Nelson C ^a   Baldwin, Lisa K ^b   Irons, Eric E ^b   Papayannopoulou, Thalia ^c   Tomlinson, Stephen ^d,e   Shayakhmetov, Dmitry M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; INTERLEUKIN 1ALPHA; PROTEOME;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CELL STRESS; CELL SURVIVAL; COMPLEMENT ACTIVATION; CONTROLLED STUDY; FLOW CYTOMETRY; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INNATE IMMUNITY; INTRACELLULAR SIGNALING; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROTEIN MICROARRAY; TISSUE INJURY; VIRUS INFECTION;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ANIMALS; CHEMOKINES; CHEMOTAXIS, LEUKOCYTE; COMPLEMENT SYSTEM PROTEINS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTERLEUKIN-1ALPHA; MACROPHAGES; MICE; MICE, INBRED C57BL; NEUTROPHILS; SIGNAL TRANSDUCTION; SPLEEN;

EID: 84897409424     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004035     Document Type: Article

References (74)

1. Khare R, Chen CY, Weaver EA, Barry MA, (2011) Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther 11: 241-258.
2. Yamamoto M, Curiel DT, (2010) Current issues and future directions of oncolytic adenoviruses. Mol Ther 18: 243-250.
3. Morral N, O'Neal WK, Rice K, Leland MM, Piedra PA, et al. (2002) Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum Gene Ther 13: 143-154.
4. Brunetti-Pierri N, Palmer DJ, Beaudet AL, Carey KD, Finegold M, et al. (2004) Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther 15: 35-46.
5. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, et al. (2003) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80: 148-158.
6. Raper SE, Yudkoff M, Chirmule N, Gao GP, Nunes F, et al. (2002) A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther 13: 163-175.
7. Lieber A, He CY, Meuse L, Schowalter D, Kirillova I, et al. (1997) The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 71: 8798-8807.
8. Shayakhmetov DM, Li ZY, Ni S, Lieber A, (2004) Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol 78: 5368-5381.
9. Smith JS, Tian J, Lozier JN, Byrnes AP, (2004) Severe pulmonary pathology after intravenous administration of adenovirus vectors in cirrhotic rats. Molecular Therapy 9: 932-941.
10. Di Paolo NC, Miao EA, Iwakura Y, Murali-Krishna K, Aderem A, et al. (2009) Virus binding to a plasma membrane receptor triggers interleukin-1α-mediated proinflammatory macrophage response in vivo. Immunity 31: 110-121.
11. Zaiss AK, Liu Q, Bowen GP, Wong NC, Bartlett JS, et al. (2002) Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 76: 4580-4590.
12. Leruez-Ville M, Minard V, Lacaille F, Buzyn A, Abachin E, et al. (2004) Real-time blood plasma polymerase chain reaction for management of disseminated adenovirus infection. Clinical Infectious Diseases 38: 45-52.
13. Ardehali H, Volmar K, Roberts C, Forman M, Becker LC, (2001) Fatal disseminated adenoviral infection in a renal transplant patient. Transplantation 71: 998-999.
14. Leen AM, Rooney CM, (2005) Adenovirus as an emerging pathogen in immunocompromised patients. British Journal of Haematology 128: 135-144.
15. Kim YJ, Boeckh M, Englund JA, (2007) Community respiratory virus infections in immunocompromised patients: Hematopoletic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Seminars in Respiratory and Critical Care Medicine 28: 222-242.
16. Lynch JP, Fishbein M, Echavarria M, (2011) Adenovirus. Seminars in Respiratory and Critical Care Medicine 32: 494-511.
17. Muruve DA, Barnes MJ, Stillman IE, Libermann TA, (1999) Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 10: 965-976.
18. Muruve DA, (2004) The innate immune response to adenovirus vectors. Hum Gene Ther 15: 1157-1166.
19. Kolaczkowska E, Kubes P, (2013) Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 13: 159-175.
20. Murray PJ, Wynn TA, (2011) Protective and pathogenic functions of macrophage subsets. Nature Reviews Immunology 11: 723-737.
21. Li Y, Muruve DA, Collins RG, Lee SS, Kubes P, (2002) The role of selectins and integrins in adenovirus vector-induced neutrophil recruitment to the liver. Eur J Immunol 32: 3443-3452.
22. Cotter MJ, Muruve DA, (2006) Isolation of neutrophils from mouse liver: A novel method to study effector leukocytes during inflammation. Journal of Immunological Methods 312: 68-78.
23. Cesta MF, (2006) Normal structure, function, and histology of mucosa-associated lymphoid tissue. Toxicologic Pathology 34: 599-608.
24. Elmore SA, (2006) Enhanced histopathology of the spleen. Toxicologic Pathology 34: 648-655.
25. Cyster JG, (2003) Lymphoid organ development and cell migration. Immunological Reviews 195: 5-14.
26. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, et al. (2000) Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrobial Agents and Chemotherapy 44: 1667-1673.
27. Gouwy M, Struyf S, Catusse J, Proost P, Van Damme J, (2004) Synergy between proinflammatory ligands of G protein-coupled receptors in neutrophil activation and migration. Journal of Leukocyte Biology 76: 185-194.
28. Dale DC, Bolyard AA, Kelley ML, Westrup EC, Makaryan V, et al. (2011) The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome. Blood 118: 4963-4966.
29. Bonig H, Chudziak D, Priestley G, Papayannopoulou T, (2009) Insights into the biology of mobilized hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 antagonist AMD3100. Experimental Hematology 37: 402-415.
30. Lukacs NW, Berlin A, Schols D, Skerlj RT, Bridger GJ, (2002) AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway Hyperreactivity. American Journal of Pathology 160: 1353-1360.
31. Di Paolo NC, Shayakhmetov DM, (2014) The analysis of innate immune response to adenovirus using antibody arrays. Methods Mol Biol 1089: 133-141.
32. Shayakhmetov DM, Li ZY, Ni SH, Lieber A, (2005) Interference with the IL-1-signaling pathway improves the toxicity profile of systemically applied adenovirus vectors. Journal of Immunology 174: 7310-7319.
33. Greber UF, Willetts M, Webster P, Helenius A, (1993) Stepwise dismantling of adenovirus 2 during entry into cells. Cell 75: 477-486.
34. Greber UF, Webster P, Weber J, Helenius A, (1996) The role of the adenovirus protease on virus entry into cells. Embo J 15: 1766-1777.
35. Chen CJ, Kono H, Golenbock D, Reed G, Akira S, et al. (2007) Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nature Medicine 13: 851-856.
36. Di Paolo NC, Shayakhmetov DM, (2013) Interleukin-1 receptor 2 keeps the lid on interleukin-1alpha. Immunity 38: 203-205.
37. Zheng Y, Humphry M, Maguire JJ, Bennett MR, Clarke MC, (2013) Intracellular interleukin-1 receptor 2 binding prevents cleavage and activity of interleukin-1α, controlling necrosis-induced sterile inflammation. Immunity 38: 285-295.
38. Dinarello CA, (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27: 519-550.
39. Dinarello CA, (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117: 3720-3732.
40. McDonald B, Kubes P, (2011) Cellular and molecular choreography of neutrophil recruitment to sites of sterile inflammation. J Mol Med (Berl) 89: 1079-1088.
41. Silva MT, (2010) When two is better than one: macrophages and neutrophils work in concert in innate immunity as complementary and cooperative partners of a myeloid phagocyte system. J Leukoc Biol 87: 93-106.
42. Di Paolo NC, Doronin K, Baldwin LK, Papayannopoulou T, Shayakhmetov DM, (2013) The Transcription Factor IRF3 Triggers "Defensive Suicide" Necrosis in Response to Viral and Bacterial Pathogens. Cell Reports 3: 1840-1846.
43. Ting JPY, Willingham SB, Bergstralh DT, (2008) NLRs at the intersection of cell death and immunity. Nature Reviews Immunology 8: 372-379.
44. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, et al. (2012) Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death and Differentiation 19: 107-120.
45. Smith JS, Xu ZL, Tian J, Stevenson SC, Byrnes AP, (2008) Interaction of systemically delivered adenovirus vectors with Kupffer cells in mouse liver. Human Gene Therapy 19: 547-554.
46. Manickan E, Smith JS, Tian J, Eggerman TL, Lozier JN, et al. (2006) Rapid Kupffer cell death after intravenous injection of adenovirus vectors. Molecular Therapy 13: 108-117.
47. Tian J, Xu ZL, Smith JS, Hofherr SE, Barry MA, et al. (2009) Adenovirus Activates Complement by Distinctly Different Mechanisms In Vitro and In Vivo: Indirect Complement Activation by Virions In Vivo. Journal of Virology 83: 5648-5658.
48. Atkinson C, He SQ, Morris K, Qiao F, Casey S, et al. (2010) Targeted Complement Inhibitors Protect against Posttransplant Cardiac Ischemia and Reperfusion Injury and Reveal an Important Role for the Alternative Pathway of Complement Activation. Journal of Immunology 185: 7007-7013.
49. Atkinson C, Song HB, Lu B, Qiao F, Burns TA, et al. (2005) Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. Journal of Clinical Investigation 115: 2444-2453.
50. Huang YX, Qiao F, Atkinson C, Holers VM, Tomlinson S, (2008) A Novel Targeted Inhibitor of the Alternative Pathway of Complement and Its Therapeutic Application in Ischemia/Reperfusion Injury. Journal of Immunology 181: 8068-8076.
51. Jiang H, Wang Z, Serra D, Frank MM, Amalfitano A, (2004) Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-Ad antibodies. Molecular Therapy 10: 1140-1142.
52. Kiang A, Hartman ZC, Everett RS, Serra D, Jiang HX, et al. (2006) Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system. Molecular Therapy 14: 588-598.
53. Xu ZL, Smith JS, Tian J, Byrnes AP, (2010) Induction of Shock After Intravenous Injection of Adenovirus Vectors: A Critical Role for Platelet-activating Factor. Molecular Therapy 18: 609-616.
54. Martineau AR, Newton SM, Wilkinson KA, Kampmann B, Hall BM, et al. (2007) Neutrophil-mediated innate immune resistance to mycobacteria. Journal of Clinical Investigation 117: 1988-1994.
55. Sharma S, Verma I, Khuller GK, (2000) Antibacterial activity of human neutrophil peptide-1 against Mycobacterium tuberculosis H37RV: in vitro and ex vivo study. European Respiratory Journal 16: 112-117.
56. Allen C, Thornton P, Denes A, McColl BW, Pierozynski A, et al. (2012) Neutrophil Cerebrovascular Transmigration Triggers Rapid Neurotoxicity through Release of Proteases Associated with Decondensed DNA. Journal of Immunology 189: 381-392.
57. Doronin K, Flatt JW, Di Paolo NC, Khare R, Kalyuzhniy O, et al. (2012) Coagulation factor X activates innate immunity to human species C adenovirus. Science 338: 795-798.
58. Alba R, Bradshaw AC, Coughlan L, Denby L, McDonald RA, et al. (2010) Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 116: 2656-2664.
59. Coughlan L, Bradshaw AC, Parker AL, Robinson H, White K, et al. (2012) Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery. Mol Ther 20: 2268-2281.
60. Belousova N, Mikheeva G, Xiong C, Soghomonian S, Young D, et al. (2010) Development of a targeted gene vector platform based on simian adenovirus serotype 24. J Virol 84: 10087-10101.
61. Sharma A, Bangari DS, Tandon M, Pandey A, HogenEsch H, et al. (2009) Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. Virology 386: 44-54.
62. Hofherr SE, Adams KE, Chen CY, May S, Weaver EA, et al. (2011) Real-time dynamic imaging of virus distribution in vivo. PLoS One 6: e17076.
63. Gautier EL, Shay T, Miller J, Greter M, Jakubzick C, et al. (2012) Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol 13: 1118-1128.
64. Movita D, Kreefft K, Biesta P, van Oudenaren A, Leenen PJ, et al. (2012) Kupffer cells express a unique combination of phenotypic and functional characteristics compared with splenic and peritoneal macrophages. J Leukoc Biol 92: 723-733.
65. Morrissey RE, Horvath C, Snyder EA, Patrick J, MacDonald JS, (2002) Rodent Nonclinical safety evaluation studies of SCH 58500, an adenoviral vector for the p53 gene. Toxicological Sciences 65: 266-275.
66. Hofherr SE, Mok H, Gushiken FC, Lopez JA, Barry MA, (2007) Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia. Human Gene Therapy 18: 837-848.
67. Stone D, Liu Y, Shayakhmetov D, Li ZY, Ni SH, et al. (2007) Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. Journal of Virology 81: 4866-4871.
68. Dinarello CA, Simon A, van der Meer JWM, (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nature Reviews Drug Discovery 11: 633-652.
69. Dinarello CA, (2004) Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Current Opinion in Pharmacology 4: 378-385.
70. Horai R, Asano M, Sudo K, Kanuka H, Suzuki M, et al. (1998) Production of mice deficient in genes for interleukin (IL)-1α, IL-1β, IL-1α/β, and IL-1 receptor antagonist shows that IL-1 beta is crucial in turpentine-induced fever development and glucocorticoid secretion. Journal of Experimental Medicine 187: 1463-1475.
71. Shornick LP, DeTogni P, Mariathasan S, Goellner J, StraussSchoenberger J, et al. (1996) Mice deficient in IL-1β manifest impaired contact hypersensitivity to trinitrochlorobenzene. Journal of Experimental Medicine 183: 1427-1436.
72. Shayakhmetov DM, Lieber A, (2000) Dependence of adenovirus infectivity on length of the fiber shaft domain. J Virol 74: 10274-10286.
73. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A, (2000) Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol 74: 2567-2583.
74. Ciavarra RP, Stephens A, Nagy S, Sekellick M, Steel C, (2006) Evaluation of immunological paradigms in a virus model: Are dendritic cells critical for antiviral immunity and viral clearance? Journal of Immunology 177: 492-500.